Shopping Cart 0
Cart Subtotal
USD 0

Parker Institute for Cancer Immunotherapy - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Parker Institute for Cancer Immunotherapy (Parker Institute), a subsidiary of The Parker Foundation is a nonprofit public benefit corporation which focuses on the development of immune therapies for the treatment of cancer. The institute coordinates together the scientists, nonprofits, academic institutions, biotechnology, and pharmaceutical industry partners to provide innovative services, tools and resources for new discoveries in cancer immunotherapy research. Its research focuses in the areas of T-cell therapies, tumor antigen discovery, tumor microenvironment and checkpoint blockade response. The institute works in collaboration with other research centers such as Memorial Sloan Kettering Cancer Center, Washington University School of Medicine, The University of Pennsylvania, Dana-Farber Cancer Institute, Stanford Medicine, and others. Parker Institute is headquartered in San Francisco, California, the US.

Parker Institute for Cancer Immunotherapy-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Parker Institute for Cancer Immunotherapy, Medical Devices Deals, 2012 to YTD 2018 9

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Tmunity Therapeutics Raises Additional USD35 Million in Series A Venture Financing 12

Tmunity Therapeutics Raises USD100 Million in Series A Venture Financing 14

ImaginAb Raises USD7.7 Million in Venture Financing 16

Partnerships 17

Parker Institute for Cancer Immunotherapy Enters into Partnership with Xyphos Biosciences 17

Inovio Pharma and Parker Institute for Cancer Immunotherapy Enter into Agreement 18

Seres Therapeutics to Enter into Partnership Agreement with MD Anderson and Parker Institute 19

Tessa Therapeutics and Parker Institute for Cancer Immunotherapy Enter into Agreement 20

Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and Cancer Research Institute Enter into Research Partnership 21

Parker Institute for Cancer Immunotherapy Enters into Agreement with PsiOxus Therapeutics 22

Parker Institute for Cancer Immunotherapy-Key Employees 23

Parker Institute for Cancer Immunotherapy-Locations And Subsidiaries 24

Head Office 24

Recent Developments 25

Government and Public Interest 25

May 15, 2018: Penn Study Finds that Different Diseases Elicit Distinct Sets of Exhausted T Cells 25

Product News 26

Apr 10, 2017: Parker Institute researchers publish first major scientific paper in Nature 26

Mar 07, 2018: Parker Institute for Cancer Immunotherapy: The battle to tame autoimmunity 27

Mar 05, 2018: Predicting Childhood Leukemia Relapse Using Machine Learning 28

Appendix 29

Methodology 29

About GlobalData 29

Contact Us 29

Disclaimer 29


List Of Figure

List of Figures

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Parker Institute for Cancer Immunotherapy, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Key Facts 2

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Parker Institute for Cancer Immunotherapy, Deals By Therapy Area, 2012 to YTD 2018 8

Parker Institute for Cancer Immunotherapy, Medical Devices Deals, 2012 to YTD 2018 9

Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Tmunity Therapeutics Raises Additional USD35 Million in Series A Venture Financing 12

Tmunity Therapeutics Raises USD100 Million in Series A Venture Financing 14

ImaginAb Raises USD7.7 Million in Venture Financing 16

Parker Institute for Cancer Immunotherapy Enters into Partnership with Xyphos Biosciences 17

Inovio Pharma and Parker Institute for Cancer Immunotherapy Enter into Agreement 18

Seres Therapeutics to Enter into Partnership Agreement with MD Anderson and Parker Institute 19

Tessa Therapeutics and Parker Institute for Cancer Immunotherapy Enter into Agreement 20

Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and Cancer Research Institute Enter into Research Partnership 21

Parker Institute for Cancer Immunotherapy Enters into Agreement with PsiOxus Therapeutics 22

Parker Institute for Cancer Immunotherapy, Key Employees 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Parker Institute for Cancer Immunotherapy, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.